Lobe Sciences Ltd. (LOBEF)
Lobe Sciences Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.05, up 0.00% on the session, giving a market capitalisation of $14.2M. On trailing twelve-month figures it carries a trailing P/E of -3.64, a net margin of 0.0%. Its beta of 0.28 implies it has historically moved less than the broad market.
Lobe Sciences Ltd. is a life sciences company focused on researching and advancing psychedelic-based medicines. Their primary therapeutic development involves psilocybin-derived treatments combined with N-acetylcysteine, specifically for addressing mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD). Additionally, they engineer specialized devices aimed at enhancing the efficiency of drug administration. This organization, headquartered in Vancouver, Canada, underwent a name change from Greenstar Biosciences Corp. to Lobe Sciences Ltd. in November 2020.
Lobe Sciences Ltd. is most often compared with the following Healthcare names: